1c:{"metadata":[["$","title","0",{"children":"NIH VideoCast - OHSRP Education Series-Considerations for Informed Consent in Cell and Gene Therapy Trials"}],["$","meta","1",{"name":"description","content":"Our speaker for this presentation is Daniel Kavanagh, PhD, RAC (Regulatory Affairs Certification). He is Senior Scientific Advisor, Gene Therapy, Vaccines, and Biologics at WCG where he serves as a scientific and regulatory lead for gene transfer research. Prior to joining WCG, he was Assistant Professor of Medicine at Harvard Medical School, and Vice Chair of the MGH-Brigham Institutional Biosafety Committee.

During this session, Dr. Kavanagh will address the following questions:

When a clinical trial involves gene therapy / human gene transfer research, what aspects of the informed consent process require special attention?
What issues pose special challenges for adult and pediatric participants?
How can IRBs and Institutional Biosafety Committees collaborate most effectively in this area?
How can participant viewpoints be engaged to improve the process?

"}],["$","meta","2",{"name":"publisher","content":"National Institutes of Health"}],["$","meta","3",{"property":"og:title","content":"NIH VideoCast - OHSRP Education Series-Considerations for Informed Consent in Cell and Gene Therapy Trials"}],["$","meta","4",{"property":"og:description","content":"Our speaker for this presentation is Daniel Kavanagh, PhD, RAC (Regulatory Affairs Certification). He is Senior Scientific Advisor, Gene Therapy, Vaccines, and Biologics at WCG where he serves as a scientific and regulatory lead for gene transfer research. Prior to joining WCG, he was Assistant Professor of Medicine at Harvard Medical School, and Vice Chair of the MGH-Brigham Institutional Biosafety Committee.

During this session, Dr. Kavanagh will address the following questions:

When a clinical trial involves gene therapy / human gene transfer research, what aspects of the informed consent process require special attention?
What issues pose special challenges for adult and pediatric participants?
How can IRBs and Institutional Biosafety Committees collaborate most effectively in this area?
How can participant viewpoints be engaged to improve the process?

"}],["$","meta","5",{"property":"og:url","content":"https://videocast.nih.gov/watch/cdc5c4a0-d5db-11f0-9cf9-12c45c580ad9"}],["$","meta","6",{"property":"og:site_name","content":"NIH VideoCast"}],["$","meta","7",{"property":"og:image","content":"https://nihcit.rev.vbrick.com/api/v2/media/videos/thumbnails/54f7397f-7a02-4bc6-9f64-5ecedb485267.jpg"}],["$","meta","8",{"property":"og:type","content":"website"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"NIH VideoCast - OHSRP Education Series-Considerations for Informed Consent in Cell and Gene Therapy Trials"}],["$","meta","11",{"name":"twitter:description","content":"Our speaker for this presentation is Daniel Kavanagh, PhD, RAC (Regulatory Affairs Certification). He is Senior Scientific Advisor, Gene Therapy, Vaccines, and Biologics at WCG where he serves as a scientific and regulatory lead for gene transfer research. Prior to joining WCG, he was Assistant Professor of Medicine at Harvard Medical School, and Vice Chair of the MGH-Brigham Institutional Biosafety Committee.

During this session, Dr. Kavanagh will address the following questions:

When a clinical trial involves gene therapy / human gene transfer research, what aspects of the informed consent process require special attention?
What issues pose special challenges for adult and pediatric participants?
How can IRBs and Institutional Biosafety Committees collaborate most effectively in this area?
How can participant viewpoints be engaged to improve the process?

"}],"$L22","$L23","$L24"],"error":null,"digest":"$undefined"}